前列腺癌
体内
曲普瑞林
化学
分子成像
癌症研究
前列腺
前列腺特异性抗原
药品
药理学
LNCaP公司
体内分布
转移
谷氨酸羧肽酶Ⅱ
抗原
亮丙瑞林
药物重新定位
正电子发射断层摄影术
药物开发
恩扎鲁胺
离体
癌症
放射性配体
分子探针
显像剂
体外
医学
基因敲除
功效
药物发现
作者
Zhuoyi Deng,Wenyuan Zhou,Chen Liu,Chao Liu,Honglei Zhang,Yifei Pei,Lulin Yang,Hua Zhu,Zhi Yang,刘特立
标识
DOI:10.1021/acs.jmedchem.6c01270
摘要
Six-transmembrane epithelial antigen of prostate 2 (STEAP2) is overexpressed in prostate cancer, yet no STEAP2-targeted imaging probes exist. Using molecular docking, we screened triptorelin and leuprorelin by radioiodine labeling and identified triptorelin as a high-affinity, selective ligand. To enhance in vivo stability and pharmacokinetics, triptorelin underwent acetylation, PEG extension, and 4-iodophenylbutyric acid conjugation, yielding five DOTA-conjugated analogs radiolabeled with 68Ga. In 22Rv1 xenografts, 68Ga-Trip-5 exhibited moderate but specific tumor uptake (SUVmax 1.8) with favorable tumor-to-background contrast. In vivo stability, biodistribution, pharmacokinetics, and human radiation dosimetry (effective dose 0.00345 mSv/MBq) demonstrated favorable safety. Autoradiography on human prostate cancer specimens showed probe accumulation correlating with endogenous STEAP2 expression. This represents the first STEAP2-targeted PET probe developed via molecular docking-guided drug repurposing. Cellular, biochemical, and imaging data provide supportive evidence of STEAP2-mediated targeting. Preclinical performance supports clinical translation of 68Ga-Trip-5, with definitive target validation.
科研通智能强力驱动
Strongly Powered by AbleSci AI